Cyclophosphamide for anemia, refractory, with excess of blasts

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Dec 2019: Trial registered, NCT04202835
  2. 14 Oct 2020: Trial started, NCT04202835

The trials

NCT04202835: ATG Plus PTCy vs ATG for CGVHD Prophylaxis

State
Under way
Phase
Phase 2
People
80 planned
Started
14 Oct 2020
Primary completion
18 May 2024
Arms
ATG/PTCy
Results
None posted
  1. 18 Dec 2019: Trial registered
  2. 14 Oct 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as ARM A Cyclophosphamide, Cycloblastin, Cyclostin, Cytophosphan, Cytoxan, Cyclophosphamide 250 mg/m2; 3 days, Cyclophosphamide 35mg/kg/day, Cyclophosphamide 500 mg/m2; 2 doses, Cyclophosphamide 500 mg/m2; 3 doses, Cyclophosphamide 900 mg/m2; 1 day, Endoxan, Neosar, Procytox, Revimmune.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.